Erlotinib vs. Crizotinib and Key Differences

Erlotinib and crizotinib are two important targeted drugs for lung cancer, each with unique treatment characteristics and indications.

Erlotinib is mainly targeted at patients with non-small cell lung cancer (NSCLC) who have sensitive mutations in the epidermal growth factor receptor (EGFR). It blocks the signal transduction of tumor cells by inhibiting the activity of EGFR tyrosine kinase, thereby inhibiting the growth and spread of tumors.

Crizotinib is a multi-target protease inhibitor, mainly targeting patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic NSCLC. It interferes with the proliferation and survival of tumor cells by inhibiting the activity of ALK and other protein kinases.

Erlotinib has shown significant efficacy in EGFR patients with sensitive mutations in NSCLC, especially in 19 exon deletion or 21 exon (L858R) mutation. It can be used as a first- or second-line treatment option for these patients.

Crizotinib is particularly suitable for ALK-positive NSCLC patients, including those who have received other chemotherapy regimens but whose disease has progressed. Crizotinib has excellent performance in reducing the risk of patient recurrence and metastasis, which can significantly improve the treatment effect and prolong the patient's life.

Common side effects of erlotinib include rash, diarrhea, nausea, etc., but they are usually mild and controllable. A small number of patients may experience serious side effects, such as abnormal liver function, which require close monitoring and timely treatment.

The side effects of crizotinib may be more complex and diverse, including liver and kidney damage, interstitial pneumonia, visual abnormalities, etc. Therefore, more caution is needed when using crizotinib and relevant indicators should be monitored regularly.